CPIX Form 4: CEO 10b5-1 purchases; direct ownership 5,700,583

Q: Who made the transactions and what is their role at CPIX?

A.J. Kazimi, the company’s Chairman and CEO, who is also listed as a Director and 10% Owner.

Q: When did the CPIX insider purchases occur and in what amounts?

Purchases of 13 shares occurred on trading days from 10/01/2025 through 10/31/2025.

Q: What prices were reported for the CPIX share purchases?

Reported prices ranged from $3.14 to $3.63 per share.

Q: What is A.J. Kazimi’s direct ownership after these transactions?

Direct beneficial ownership is 5,700,583 shares following the latest reported transaction.

Q: Were the transactions made under a Rule 10b5-1 plan?

Yes. The filing states they occurred automatically under a Rule 10b5-1 trading plan adopted on November 14, 2024.

Cumberland Pharmaceuticals (CPIX) reported insider acquisitions by Chairman & CEO A.J.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cumberland Pharmaceuticals (CPIX) reported insider acquisitions by Chairman & CEO A.J. Kazimi on a Form 4. The filing lists a series of 13-share purchases on multiple days from 10/01/2025 through 10/31/2025, executed under a Rule 10b5-1 trading plan.

Reported prices ranged from $3.14 to $3.63 per share across the period. Following the latest transaction, Kazimi’s direct beneficial ownership is 5,700,583 shares.

Insider Trade Summary

Small Acquisition: 299 shares

Small Acquisition 23 txns

Insider KAZIMI A J

Role Chairman and CEO

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock	13	$3.39	$44.07
Small Acquisition	Common Stock	13	$3.29	$42.77
Small Acquisition	Common Stock	13	$3.26	$42.38
Small Acquisition	Common Stock	13	$3.28	$42.64
Small Acquisition	Common Stock	13	$3.49	$45.37
Small Acquisition	Common Stock	13	$3.51	$45.63
Small Acquisition	Common Stock	13	$3.44	$44.72
Small Acquisition	Common Stock	13	$3.62	$47.06
Small Acquisition	Common Stock	13	$3.61	$46.93
Small Acquisition	Common Stock	13	$3.52	$45.76
Small Acquisition	Common Stock	13	$3.48	$45.24
Small Acquisition	Common Stock	13	$3.49	$45.37
Small Acquisition	Common Stock	13	$3.37	$43.81
Small Acquisition	Common Stock	13	$3.35	$43.55
Small Acquisition	Common Stock	13	$3.54	$46.02
Small Acquisition	Common Stock	13	$3.59	$46.67
Small Acquisition	Common Stock	13	$3.56	$46.28
Small Acquisition	Common Stock	13	$3.63	$47.19
Small Acquisition	Common Stock	13	$3.19	$41.47
Small Acquisition	Common Stock	13	$3.14	$40.82
Small Acquisition	Common Stock	13	$3.25	$42.25
Small Acquisition	Common Stock	13	$3.28	$42.64
Small Acquisition	Common Stock	13	$3.31	$43.03

Holdings After Transaction: Common Stock — 5,700,583 shares (Direct)

Footnotes (1)

F1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CPIX disclose in this filing?

A Form 4 reporting insider acquisitions of Cumberland Pharmaceuticals common stock by A.J. Kazimi.

Who made the transactions and what is their role at CPIX?

A.J. Kazimi, the company’s Chairman and CEO, who is also listed as a Director and 10% Owner.

When did the CPIX insider purchases occur and in what amounts?

Purchases of 13 shares occurred on trading days from 10/01/2025 through 10/31/2025.

What is A.J. Kazimi’s direct ownership after these transactions?

Direct beneficial ownership is 5,700,583 shares following the latest reported transaction.

Were the transactions made under a Rule 10b5-1 plan?

Yes. The filing states they occurred automatically under a Rule 10b5-1 trading plan adopted on November 14, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/03/2025 - 07:56 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAZIMI A J

(Last)

(First)

(Middle)

1600 WEST END AVE.

SUITE 1300

(Street)

NASHVILLE

37203

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2025		L	V	13⁽¹⁾	A	$3.31	5,700,297	D
Common Stock	10/02/2025		L	V	13⁽¹⁾	A	$3.28	5,700,310	D
Common Stock	10/03/2025		L	V	13⁽¹⁾	A	$3.25	5,700,323	D
Common Stock	10/06/2025		L	V	13⁽¹⁾	A	$3.14	5,700,336	D
Common Stock	10/07/2025		L	V	13⁽¹⁾	A	$3.19	5,700,349	D
Common Stock	10/08/2025		L	V	13⁽¹⁾	A	$3.63	5,700,362	D
Common Stock	10/09/2025		L	V	13⁽¹⁾	A	$3.56	5,700,375	D
Common Stock	10/10/2025		L	V	13⁽¹⁾	A	$3.59	5,700,388	D
Common Stock	10/13/2025		L	V	13⁽¹⁾	A	$3.54	5,700,401	D
Common Stock	10/14/2025		L	V	13⁽¹⁾	A	$3.35	5,700,414	D
Common Stock	10/15/2025		L	V	13⁽¹⁾	A	$3.37	5,700,427	D
Common Stock	10/16/2025		L	V	13⁽¹⁾	A	$3.49	5,700,440	D
Common Stock	10/17/2025		L	V	13⁽¹⁾	A	$3.48	5,700,453	D
Common Stock	10/20/2025		L	V	13⁽¹⁾	A	$3.52	5,700,466	D
Common Stock	10/21/2025		L	V	13⁽¹⁾	A	$3.61	5,700,479	D
Common Stock	10/22/2025		L	V	13⁽¹⁾	A	$3.62	5,700,492	D
Common Stock	10/23/2025		L	V	13⁽¹⁾	A	$3.44	5,700,505	D
Common Stock	10/24/2025		L	V	13⁽¹⁾	A	$3.51	5,700,518	D
Common Stock	10/27/2025		L	V	13⁽¹⁾	A	$3.49	5,700,531	D
Common Stock	10/28/2025		L	V	13⁽¹⁾	A	$3.28	5,700,544	D
Common Stock	10/29/2025		L	V	13⁽¹⁾	A	$3.26	5,700,557	D
Common Stock	10/30/2025		L	V	13⁽¹⁾	A	$3.29	5,700,570	D
Common Stock	10/31/2025		L	V	13⁽¹⁾	A	$3.39	5,700,583	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	A.J. Kazimi by /s/ John Hamm as attorney-in-fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR